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Recent  studies  have  indicated  that  the  initiation  and  maintenance  of  T  cell 
proliferation is  mediated  by a  soluble T  cell  growth  factor  [TCGF(IL2)] t  released 
from lectin- or antigen-activated mononuclear cells (1, 2). Although it was shown that 
immunocompetent,  Thy-l-positive cells were required for the release of TCGF(IL2) 
(3,  4),  it  was  possible that  the  adherent  cell product,  lymphocyte-activating factor 
[LAF(IL1)]  1 (5), was responsible for the T  cell growth.  It was  found,  however,  that 
LAF(IL1)  had  no  TCGF(IL2)  activity, whereas  partially purified TCGF(IL2)  was 
readily detectable in the LAF(IL1) assay (6). One explanation for these observations, 
was  the  possibility that  LAF(IL1)  might  promote  the  production  of T  cell-derived 
TCGF(IL2).  In this report, we describe the results of experiments that  support  this 
hypothesis. 
Materials  and  Methods 
Animals.  C57BL/6 and C3H/HeJ  mice, 5-7 wk of age, were purchased from The Jackson 
Laboratory, Bar Harbor, Maine. BALB/c female, athymic, nu/nu  (nude) mice, 5-7 wk of age 
were purchased from ARS/Sprague-Dawley Div., GIBCO/Invenex Div., Madison, Wis. 
Cell Fractionation Procedures.  Adherent cell-depleted, T  cell-enriched splenocyte populations, 
and adherent splenocyte populations were prepared and utilized as described in detail previ- 
ously (4). 
LAF(IL1) Preparations.  Murine conditioned medium that contained LAF(ILI) was derived 
from either unsolicited C57BL/6 peritoneal cells or PU5-1.8 cells (7) that were cultured (2 × 
106 cells/ml) in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum 
(FCS), and 10/tg/ml lipopolysaccharide (LPS) (Grand Island Biological Co., Grand Island, N. 
Y.). After 4 d of culture, the supernate was harvested, clarified by centrifugation (1,000 g for 10 
min), and dialyzed against  1,000 volumes of RPMI-1640 medium for 24 h. The conditioned 
medium was then filtered through a 0.2q~m filter (Millipore Corp., Bedford, Mass.) and stored 
at 4°C until used. 
Human  LAF(IL1) was obtained from LPS (20 btg/ml)-stimulated peripheral blood mono- 
nuclear cells and  partially purified by ultrafiltration using a  hollow fiber filtration device, 
followed by isoelectric focusing with a sucrose gradient as previously described (8). Based upon 
the specific activity of LAF(IL1) present in the starting material, there was a  >25,000-fold 
purification after these steps. 
Before use in experiments designed to test the effect of LAF(IL1) on TCGF(IL2) production, 
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the samples were titered in a LAF(IL1) assay (see below) and the concentrations which yielded 
50% maximal activity were selected  (usually a  1:10 dilution). All LAF(IL1) preparations were 
screened  for TCGF(IL2) activity in the presence and absence of lectin  using the TCGF(IL2) 
microassay (see below) and were found to be negative. 
TCGF(IL2)  Production.  TCGF(IL2)  for  use  in  experiments  to  determine  the  effect  of 
dexamethasone  (DEX)  on  tritiated  thymidine  ([3H]Tdr)  incorporation  by tbymocytes was 
produced by the 24-h stimulation ofC57BL/6 splenocytes  (1 ×  10  cells/ml) with concanavalin 
A (Con-A; 2.5/~g/ml; Miles-Yeda  Laboratories, Rehoveth, Israel] as previously described  (4). 
In experimentation designed  to monitor TCGF(IL2) produced by different  murine cell popu- 
lations, responding cells (1 ×  10  7 cells/ml) were stimulated with Con-A (2.5 gg/ml) for various 
time periods  (Results) as previously described  (9). At the conclusion  of the culture periods,  the 
cells were  removed by centrifugation  (1,000 g  for  10  min)  and  the  supernates  assayed for 
TCGF(IL2) activity. 
Assays for  LAF(ILI) and  TCGF(IL2).  LAF(IL1)  activity  was  determined  by  the  dose- 
dependent  augmentation of phytohemagglutinin  (PHA)-initiated thymocyte proliferation as 
described by Lachman et al. (8), with the exception that serial twofold dilutions of each sample 
were performed. 
In experiments where the effect of DEX on LAF(IL1) and TCGF(IL2) activity was tested, 
DEX (Steraloids,  Inc., Hancock, N. H.) was prepared and added to the cultures in concentra- 
tions from 0.1 to 100 nM as described  previously (10). 
TCGF(IL2) activity was assayed as described in detail previously (3) using CTLL-2 cells as 
the indicator cell population. The results were quantified by probit analysis and expressed  as 
units of activity based on a standard rat TCGF(IL2) preparation. 
Results 
The requirement  for both T  cells and adherent cells for the release of TCGF(IL2) 
upon lectin stimulation is displayed in Fig.  1 A. Although unfractionated splenocytes 
released easily measurable  quantities  of TCGF(IL2), the separation  of cells  into T 
cell-enriched and adherent cell-enriched fractions resulted in a marked diminution of 
TCGF(IL2) production.  Reconstitution  of the T  cell-enriched population  with only 
1-5% adherent cells completely restored the response. 
Although  these data  favored the hypothesis that  TCGF(IL2)  was T  cell derived, 
they also indicated  that  adherent  cells played an  essential  role.  Because  LAF(IL1) 
was known to markedly augment lectin-initiated  proliferation of thymocytes (which 
contain  <1%  macrophages)  and adherent  cell-depleted  splenic T  cells,  experiments 
were performed to examine the effect of LAF(IL1) on TCGF(IL2) release. As displayed 
in Fig.  1 B, in the absence oflectin, LAF(IL1) had no effect on TCGF(IL2) production 
by nylon column-enriched  splenic T  cells:  both LAF(IL1)  and lectin were required 
for optimal TCGF(IL2) release. Peak levels of TCGF activity were found after 2 d of 
culture, and detectable activity declined thereafter. The dual effect of LAF(IL1) and 
lectin on TCGF(IL2) production, and the resultant proliferation of both thymocytes 
and splenic T-cells is evident from the experiment displayed in Table I. Of note was 
the direct correlation between the amount of TCGF detectable on the second day of 
culture and the peak cellular proliferative response as indicated by [3H]Tdr incorpo- 
ration  1 d later. 
In a  previously reported series of experiments (10), we found that  glucocorticoids 
suppressed antigen- or lectin-initiated T  cell proliferation primarily by inhibition  of 
TCGF(IL2)  release,  although  there  was  only  a  slight  inhibition  (20-30%)  of 
TCGF(IL2)-driven T  cell  proliferation.  If LAF(IL1)  functioned  to provide a  signal 
necessary for TCGF(IL2) production, and if TCGF(IL2) release was essential for the 
proliferative cellular response, then it might be expected that glucocorticoids would 
abrogate  LAF(IL1)  activity.  The  glucocorticoid  dose-dependent  inhibition  of SMITH  ET  AL.  BRIEF  DEFINITIVE  REPORT  1553 
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FIG.  1.  (A)  the production of TCGF(IL2)  by different cell populations. Cells (1  ×  107 cells/ml) 
were cultured  for  24  h  in  the presence of Con-A  (2.5 #g/ml)  before  the assay of supernates for 
TCGF(IL2)  activity. Vertical brackets depict  I  SD about the mean of three experiments. (B)  The 
effect of LAF(IL 1) on TCGF(IL2) production by splenic T  cells. LAF(IL l) was obtained from LPS- 
stimulated human mononuclear cells and partially purified by diafiltration and isoelectric focusing. 
Cells (1  ×  107 cells/ml) were cultured with:  (O)  medium; (A)  LAF(ILI);  (O)  1% PHA-M  (Difco 
Laboratories,  Detroit,  Mich.);  (A)  1%  PHA-M  +  LAF(ILl).  Supernates were  removed from the 
cultures on the days indicated and tested for TCGF(1L2) activity. 
Fio.  2.  (A)  The effect of DEX on:  (O)  murine LAF(ILl)-induced and (O)  TCGF(IL2)-induced 
thymocyte [aH]Tdr incorporation. Vertical  brackets depict  1 SD about the mean of three experi- 
ments. (B) The effect of LAF(IL1) on lectin-initiated [aH]Tdr incorporation of normal thymocytes 
(closed  symbols)  and  athymic  (nu/nu)  splenocytes (open  symbols). LAF(ILI)  was  derived  from 
LPS-stimulated murine peritoneal  cells  (circles),  and  LPS-stimulated human  mononuclear cells 
(squares). 
TABLE I 
LAF(IL1)*-induced TCGF Release and the T Cell Response 
Stimuli 
Thymocytes 
TCGF(IL2)~:  [3H]Tdr incorporation§ 
Splenic T cells 
TCGF(IL2):~  [ZH]Tdr incorporation§ 
#ml  cpm  wnl  cpm 
Medium  0.00  186 ±  10  0.00  345 ± 32 
Con-A  0.04  5,805 ± 861  0.16  22,190 ± 968 
LAF(IL1)  0.00  516 ± 5  0.00  402 + 39 
LAF (I L 1  ) + Con-A  1.30  177,920 ± 4,940  0.88  120,517 ± 2,923 
* LAF(ILI)  was derived from LPS (20 p.g/ml)-stimulated PU5-1.8 cells. 
:~ TCGF(IL2)  activity was assayed on culture fluid samples harvested 2 d after the initiation of the culture. 
§ [aH]Tdr incorporation  was determined 3 d after the initiation of the culture. 
LAF(IL  1) activity as determined by [ZH]Tdr incorporation of thymocytes is shown in 
Fig. 2 A. One-half maximal suppression occurred at a concentration of 1.5 nM DEX, 
and complete inhibition occurred at  100  nM DEX, a  concentration which we had 
previously  found  almost  completely saturated  thymocyte glucocorticoid  receptors 
(10). Also shown in Fig. 2 A is the effect of DEX on TCGF(IL2)-mediated thymocyte 
proliferation. There was no inhibition observed at 0.1-10  nM DEX, and only 20% 
suppression of the proliferative response occurred at  100 nM DEX. These results are 
consistent with our previous data (10),  and they support the hypothesis that gluco- 
corticoids inhibit TCGF(IL2) release by a  direct interference with LAF(IL1) stimu- 
lation of TCGF(IL2) production by T  cells, rather than by suppressing the prolifer- 
ative response to TCGF(IL2). 
As a  final approach to revealing the mechanism by which LAF(IL1) potentiates 
lymphocyte proliferation, we examined the effect of LAF(ILI) on cells from nude 
mice. In previously reported experiments (9), we observed that lymphoid cells from 1554  SMITH ET AL.  BRIEF  DEFINITIVE REPORT 
nude  mice  were  incapable  of releasing  detectable  TCGF(IL2)  activity,  yet  were 
capable of a  vigorous proliferative response in the presence of lectin or alloantigen, 
provided TCGF(IL2) was supplied exogenously. If LAF(ILI) promoted T  cell prolif- 
eration via the facilitation of TCGF(IL2  )  release from thymic-dependent cells, then 
one would expect LAF(IL1) to have no effect on nude mouse splenocytes. As shown 
in  Fig.  2B,  neither  LAF(IL1)-containing  medium,  nor  partially  purified  human 
LAF(IL1)  promoted  a  detectable response  from  nude  mouse  splenocytes,  whereas 
these same  LAF(IL1)  preparations  clearly mediated  dose-dependent stimulation  of 
thymocyte [3H]Tdr incorporation. 
Discussion 
The results of this study indicate that one mechanism by which activated macro- 
phages  participate in  the promulgation  of a  T  cell proliferative response is via the 
release of LAF(IL1), which is essential for the production of TCGF(IL2) by T  cells. 
Thus, among the cells involved in the reaction, there are at  least two hormone-like 
soluble cell products, which  function to regulate the magnitude of the  final T  cell 
proliferative  response.  That  LAF(IL1)  promotes  T  cell  proliferation  through  the 
stimulation  of TCGF(IL2)  production  was  suggested  by  several  experimental  ap- 
proaches:  small  numbers  of adherent  cells were required  to maximize TCGF(IL2) 
release from thymocytes or adherent cell-depleted splenocytes; LAF(IL1) effectively 
replaced  the  requirement  for  adherent  cells;  glucocorticoids,  which  abrogate 
TCGF(IL2) production, completely inhibited the LAF(IL1) effect on lectin-initiated 
thymocyte proliferation; LAF(IL1) had no proliferative effect on nude mouse splen- 
ocytes, which are incapable of TCGF(IL2) production. 
In addition to the requirement for the presence of LAF(IL1) and TCGF(IL2), the 
quantity of each of these soluble factors dictates the extent of T  cell clonal expansion. 
The dose-dependency of the LAF(IL1) effect on T  cell proliferation is evident from 
Fig. 2 B, and the dose-dependency of the TCGF(IL2) effect has been noted previously 
(3). It is this dose effect which serves as the basis for the quantitation of each of these 
factors  in  their  respective assays.  Because  TCGF(IL2)  ultimately  mediates  T  cell 
proliferation (1-4), and because the magnitude of TCGF(IL2) production is depen- 
dent upon the quantity of LAF(IL 1) available to TCGF(IL2)-producer cells, the data 
indicate that LAF(IL1) and TCGF(IL2) function in a bimodal amplification system 
which  finally  determines  the  extent  of antigen-  or  lectin-initiated  T  cell  clonal 
expansion. 
The LAF(IL1) preparations used  for the experiments reported here were derived 
from LPS-stimulated murine or human adherent cells.  Mizel et al. have shown that 
LPS caused the release of LAF(IL1)  from adherent  cells in  the absence of T  cells, 
whereas  T  cells  were  required  for  the  release  of LAF(ILI)  from  macrophages  in 
response to T cell lectins or antigens (11). Because we had previously determined that 
LPS did not cause the release of detectable TCGF(IL2)  (3), we could be confident 
that the LAF(IL1) preparations used for these experiments were free of any contam- 
inating TCGF(IL2). Aside from considerations of experimental design, the effect of 
LPS on LAF(IL 1) release, and the realization that T cell clonal expansion is indirectly 
[through TCGF(IL2)] dependent upon the quantity of LAF(ILI) available, suggests 
that  much  of the  adjuvant  effect of LPS  may be  mediated  by the  stimulation  of 
LAF(IL1)  release.  Thus,  as  has  been  suggested  (5),  one  could  explain  the  LPS- SMITH ET AL.  BRIEF  DEFINITIVE REPORT  1555 
augmentation of both the cell-mediated and humoral immune response at least in 
part  by  the  effect  on  adherent  cells:  enhanced  LAF(IL1)  release  would  amplify 
TCGF(IL2)  release.  In  that  both  cytotoxic  and  helper  T  cell  proliferation  is 
TCGF(IL2) dose-dependent (12,  13), the final result would be a marked expansion of 
these  functional T  cell  populations.  The  implication of these observations is  that 
because the production and actions of both LAF(IL  1) and TCGF(IL2) can be assayed 
separately,  it  may  be  possible  for  the  first  time  to  identify  the  target  cells  of 
immunological adjuvants and to define their mode of action. 
A similar approach could also be applied to the study ofimmunosuppressive agents. 
For  example,  the  consequences  of the  interruption  of the  LAF(IL1)-TCGF(IL2) 
amplification network  is  evident  from  the  experiments  detailed  on  the  effects of 
glucocorticoids (Fig. 2 A). Because glucocorticoids primarily functioned to inhibit the 
effect of LAF(IL1) in promoting production of TCGF(IL2), rather than preventing 
the T  cell proliferative response to TCGF(IL2), saturating concentrations of gluco- 
corticoid impeded the initial steps in the reaction, resulting in a complete suppression 
of T  cell proliferation. That the addition of TCGF(IL2) circumvented glucocortocoid 
suppression suggests that an increased understanding of the mechanisms of action of 
glucocorticoids and other immunosuppressive agents may allow for the design of new, 
more specific immunosuppressive therapeutic approaches. 
A final implication of this study may be drawn from the observations made with 
nude mouse lymphoid cells.  In this instance, LAF(IL1)-responsive TCGF(IL2)-pro- 
ducer cells appear to be either nonfunctional or lacking. In previously reported studies 
(14), adherent cells from nude mice were found to release even greater quantities of 
LAF(IL1) than cells from normal mice, and in other studies (9), TCGF(IL2)-responsive 
cells were  demonstrated to  be  present  in  nude  mouse lymphoid cell  populations. 
Because TCGF(IL2) was capable of promoting the in vitro proliferation and genera- 
tion of cytolytic nude mouse T cells, we questioned whether TCGF(IL2) replacement 
therapy would by-pass the defect in TCGF(IL2) production and restore T cell function 
to  nude  mice.  Indeed, we  have  recently demonstrated that  the  administration  of 
TCGF(IL2) to nude mice, followed by alloimmunization, results in the appearance of 
splenocytes capable of proliferation and differentiation to alloantigen-specific cytolytic 
effector cells (15). 
Summary 
The  mechanism  of the  lymphoproliferative effect  of the  macrophage  product 
lymphocyte-activating factor [LAF(IL1)]  1 appears to be mediated by the stimulation 
of the release of T  cell growth factor [TCGF(IL2)] x by T  cells. The magnitude of the 
resultant T  cell proliferative clonal expansion is thus dependent upon the quantity of 
both  LAF(IL1)  and  TCGF(IL2)  induced  by  antigen  or  lectin  stimulation.  These 
observations, coupled with the ability to measure the production and actions of these 
hormone-like lymphokines, should allow for increased insight into the mode of action 
of immunoenhancing and immunosuppressive agents, as well as for new therapeutic 
approaches to disease states involving T  lymphocytes. 
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